Eli Lilly is investing in AI-powered clinical documentation while facing new obesity drug competition from Pfizer, reshaping its growth outlook.

What happened

Eli Lilly invested in Abridge, an AI-enabled clinical documentation company, to improve trial enrollment and real-world evidence generation. At the same time, Pfizer is developing an injectable obesity treatment that could be administered only once a month, introducing fresh competition to Lilly's established weight-loss injectable franchise.

Why it matters

The Abridge partnership could give Lilly earlier visibility into real-world treatment patterns and patient eligibility for trials, potentially helping it run more efficient studies. However, Pfizer's monthly injectable and existing competition from Novo Nordisk raise the risk of pricing pressure and tighter payer controls in the obesity market, where a large share of prescriptions are linked to price-sensitive self-pay customers.

What to watch

Track how quickly Abridge's AI tools move from pilot use into Lilly-linked studies and whether that translates to faster trial enrollment. On the obesity side, monitor head-to-head clinical data, dosing convenience, and payer coverage decisions as Pfizer's monthly injectable and oral competitors advance, since those factors can shape both volume and pricing for Lilly's GLP 1 franchise.